14 results about "Neutralizing epitope" patented technology

This invention provides a broad-spectrum mRNA vaccine for the prevention of feline infectious peritonitis (FIP) and its preparation method. The vaccine comprises mRNA molecule 1 and mRNA molecule 2. mRNA molecule 1 contains an LS-FIPV-I MEV-N-M antigen protein coding sequence composed of a self-assembled LS nanoparticle fusion sequence based on a tandem neutralizing epitope of the FIPV type I S protein and a T-cell epitope, as well as antigen-coding sequences of the N and M proteins. mRNA molecule 2 contains an antigen protein coding sequence of an LS nanoparticle structure self-assembled from the FIPV type II S protein receptor domain RBD. This invention, through the combination of two mRNA molecules, can achieve broad-spectrum protection against both FIPV types I and II while mitigating the risk of adverse drug reaction (ADE).

The invention discloses a high-stability and informatization-adaptive chemiluminescence mixed indoor quality control product for infectious disease projects and a preparation method thereof. The method is characterized in that inactivated healthy human serum is used as a non-infectious optimized matrix, a single kit covers all infectious disease A and B immunodetection items specified by the National Health Committee, and three concentration gradients of negative, weak positive and strong positive are set. Through cooperation of a recombinant non-neutralizing epitope antigen, a high-specificity monoclonal antibody and a double-blocking system, interference-free coexistence of multiple items is realized, and the cross reaction rate is less than or equal to 1.0%; a four-dimensional synergistic compound long-acting stable system is adopted, and it is ensured that the activity retention rate is larger than or equal to 95.0% after 24 months of storage at 2-8 DEG C. The product is packaged in a special direct on-machine test tube, is matched with a fixed identity code of a pre-associated laboratory information system, supports two-way communication with an automatic instrument, and realizes no manual intervention in the whole process of quality control. The preparation process is standardized, is suitable for clinical laboratories of all levels of medical institutions, and promotes import and substitution of high-end quality control products.

This invention provides a broad-spectrum non-neutralizing antibody against foot-and-mouth disease virus (FMD) and its application in the preparation of reagents that enhance the production of neutralizing antibodies, belonging to the field of antibody technology. The FMD virus broad-spectrum non-neutralizing antibody has the amino acid sequence of its heavy chain variable region as shown in SEQ ID NO:1 and the amino acid sequence of its light chain variable region as shown in SEQ ID NO:2. This invention utilizes single B-cell antibody technology to screen and obtain a porcine broad-spectrum non-neutralizing monoclonal antibody SP1C6, which can recognize a conformational epitope on VP2. The broad-spectrum non-neutralizing antibody SP1C6 increases the level of neutralizing antibodies induced by FMD virus in pigs by blocking the non-neutralizing epitopes of the FMD virus antigen.

This invention discloses an RSV pre-F trimer protein combination and its application in the preparation of a bivalent RSV vaccine, relating to the field of human vaccine technology. The vaccine is prepared by mixing equal masses of RSV-A and RSV-B subtype pre-F trimer proteins and adding 0.35 mg / 0.5 mL of aluminum hydroxide adjuvant. Both F proteins have their p27 fragment and C-terminal esterification region deleted, and F2 / F1 are linked by GSGSGS. Interchain disulfide bonds are introduced at S146C / N460C and A149C / Y458C sites, and intrachain disulfide bonds are introduced at S155C / S290C sites. After secretion and expression by CHO cells, the pre-F trimer spontaneously assembles into a stable pre-F trimer. The vaccine does not require lyophilization and maintains high purity and the integrity of neutralizing epitopes after storage at 37°C for 28 days. It can significantly induce neutralizing antibodies and T-cell immunity and can be used to prevent various RSV-A / B infections.

The application discloses a multi-epitope fusion protein based on porcine rotavirus VP7 and VP8 double targets and a preparation method and application thereof. S.T As a skeleton, the advantages of precisely integrating VP7 and VP8 neutralizing epitopes are constructed into multi-epitope fusion antigen FliC S.T -VP7+VP8. The fusion protein has two immunological advantages: FliC S.T The skeleton has TLR5 adjuvant activity, can efficiently activate the innate immunity and adaptive immunity of a host, and can synchronously present key neutralizing epitopes of porcine rotavirus VP7 and VP8 through a multi-epitope strategy, so that high-titer specific neutralizing antibodies and strong cellular immune responses against the two structural proteins can be induced in the body. The application provides a multi-epitope fusion antigen of porcine rotavirus which integrates high immunogenicity and broad-spectrum neutralization protection, and provides a feasible technical scheme for the prevention and control of porcine rotavirus.

Provided herein are compositions including a binding reagent for a Zika virus (ZIKV) epitope, pharmaceutical compositions including such binding reagents, and methods of detecting ZIKV binding antibodies and ZIKV neutralizing antibodies in patients.

The application provides a method for identifying neutralizing antigen epitopes in bovine coronavirus spike protein, immunogens, compositions and uses, relates to the technical field of biology, and specifically constructs an efficient neutralizing epitope identification route: online prediction, nanoparticle multivalent display, animal immunization, combined evaluation of binding and neutralization, which can screen out epitopes with neutralizing activity from candidate linear epitopes in a relatively short period of time; the multivalent presentation of ferritin nanoparticles significantly improves the detectability of the immune response of weak immunogenic linear peptides; the obtained epitopes can directly serve the development of subunit vaccines, multi-epitope nanovaccines and in vitro diagnostic reagents.

The invention provides a broad-spectrum mRNA vaccine for preventing feline infectious peritonitis and a preparation method thereof, the vaccine comprises an mRNA molecule 1 and an mRNA molecule 2, the mRNA molecule 1 comprises a self-assembled LS nanoparticle fusion sequence based on a neutralizing epitope of series FIPV type I S protein and a T cell epitope, and the mRNA molecule 2 comprises a self-assembled LS nanoparticle fusion sequence based on series FIPV type I S protein. The LS-FIBV-I MEV-N-M antigen protein coding sequence is composed of the antigen coding sequences of the N protein and the M protein; the mRNA molecule 2 comprises an antigen protein coding sequence which is fused and self-assembled by an FIPV II type S protein receptor structural domain RBD and has an LS nano-particle structure. According to the invention, through the combination of double mRNA molecules, while the ADE risk is avoided, the broad-spectrum protection of the FIPV type I and the FIPV type II is realized.

This invention provides a modified hemagglutinin (HA) protein for preparing a broad-spectrum vaccine against H9 avian influenza, a broad-spectrum vaccine based on the HA protein, a preparation method, and applications. The modified HA protein is obtained through the following strategy: consensus sequences are constructed as immunogenic backbones for the HA sequences of H9 avian influenza viruses at different epidemic periods; based on this, two types of functional mutations are directionally introduced: one type involves transplanting key epitope residues targeted by known broad-spectrum antibodies, and the other type involves neutralizing epitope residues predicted based on viral evolutionary patterns. The modified HA protein of this invention can maintain a highly similar overall fold and trimer interface to the wild type, can be efficiently expressed in eukaryotic systems, and can induce high levels of neutralizing antibodies with broad-spectrum cross-protective effects in target animals. It provides a core antigen candidate for the development of a new generation of H9 broad-spectrum vaccines and has broad application prospects.

The invention relates to the technical field of biological medicines and vaccines, in particular to a multi-epitope fusion antigen, a protein, a vaccine and application thereof. The amino acid sequence of the multi-epitope fusion antigen is as shown in SEQ ID NO: 1. According to the present invention, by screening the conservative neutralizing epitope in the SARS S2 region and reasonably designing the multi-epitope fusion antigen, the problem of insufficient protection of the existing novel coronavirus vaccine on the variant is solved, the broad-spectrum protection of the various novel coronavirus variants is achieved, and the broad application prospect is provided.

The invention relates to the technical field of biological medicines and vaccines, in particular to a multi-epitope peptide based on novel coronavirus and application of the multi-epitope peptide. The multi-epitope peptide is formed by connecting neutralizing epitope peptides with amino acid sequences as shown in SEQ ID NO: 1-11 through flexible connecting peptides. According to the invention, by screening the conservative neutralizing epitope in the SARS-COV2 S2 region and reasonably designing the multi-epitope fusion protein, the problem that the existing novel coronavirus vaccine is insufficient in protection of variants is solved, the broad-spectrum protection of various novel coronavirus variants is realized, and the application prospect is wide.

The invention provides an African swine fever virus-like particle and application thereof in preparation of an African swine fever virus vaccine, and relates to the technical field of biology. The capsid protein, the protein A, the protein B and the protein C provided by the invention have good immune effects and can be used in African swine fever virus vaccines. Wherein the protein C is a four-layer nested particle and maintains a three-dimensional conformation of neutralizing epitopes on the surface of the particle, so that the structural rigidity of the particle is enhanced, and a better immune effect is achieved.

The application discloses a preparation method of a PEDV COE subunit vaccine targeting M cells and application thereof. The application connects RGD peptide targeting M cells, a core neutralizing epitope COE region on a PEDV S protein and a fluorescent protein, expresses a recombinant protein, introduces a sulfur-containing amino acid into the protein to facilitate modification of the recombinant protein and connection of the protein to other substances in a covalent bond mode, and obtains a safe and effective mucosal subunit vaccine with green fluorescent labeling. Unlike common vaccines, the antigen of the vaccine can not only be directly taken by dendritic cells, but also be presented to dendritic cells through targeting M cells, the antigen presentation efficiency is significantly improved, the downstream immunity is more effectively started, and a series of immune responses of the body are induced, so that the mucosal immune system of the body produces a large number of PEDV specific antibodies to resist invasion of external pathogens, and the effect of specific immune protection is achieved.